COPENHAGEN, Denmark, Sept. 01, 2021 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients’ lives, today announced the pricing of its underwritten public offering of 2,500,000 American Depositary Shares (“ADSs”), each of which represents one ordinary share of Ascendis, at a price to the public of $160.00 per ADS. All of the ADSs are being offered by Ascendis.